33. B-Cell Depleting Therapies and COVID-19
ACR on Air
00:00
The Effects of Dosing Retuximab on the Return of B Cells
There is a loose association between the interim length between your last dose of retuximab and then when you get vaccinated. The longer that period, the more likely you're out to generate good, humeral responses. And this largely correlates with the return of B cells. But there's data that was published maybe a couple months ago from people who were B cell depleted and had really poor responses after the second dose; they still had very poor responses. Of those that did have good responses, they tend to be further out from the last B cell depleting therapy.
Transcript
Play full episode
